Table 2.
The Treatment Regimens and Outcomes of the 21 Patients
| No. | Immunosuppressive Agents | The Time Interval from Postoperative Immunosuppressive Therapy to the Onset of Symptoms or Disease Changes (Months) | The Time Interval from Invasion to Antifungal Therapy (Days) | The Use of Immunosuppressive Agents During Invasion | Antifungal Drugs | Outcome |
|---|---|---|---|---|---|---|
| P3 | Azathioprine | N | N | N | Amphotericin B 2 days | Died |
| P4 | Azathioprine+CsA/Tac+PED | 48 | N | N | None | Died |
| P5 | Tac+PED5mg qd | 31 | 60 | Reduced Tac dosage | Liposomal amphotericin B 100mg qd, followed by Itraconazole 1 year | Improved |
| P6 | Tac+MMF+PED | 9 | 17 | Reduced Tac dosage, withheld MMF | Amphotericin B 0.5mg/kg/day 30 days, followed by Itraconazole 200mg qd | Improved |
| P7 | Tac3mg bid+ PED5mg qd | 7 | 60 | N | Liposomal amphotericin B 2mg/kg/day 21 days, followed by Itraconazole 200mg qd | Improved |
| P8 | Tac1mg bid+MMF1000 mg bid + PED10mg qd | 48 | 21 | Reduced Tac dosage | Liposomal amphotericin B 3mg/kg/day 21 days, followed by Itraconazole 300mg 3 months | Improved |
| P9 | Tac2-3mg bid+MMF750mg bid | 60 | 30 | N | Voriconazole 200mg qd, followed by Itraconazole 200mg bid 2 weeks | Improved |
| P10 | Tac | 11 | N | N | # | Died |
| P11 | Tac+MMF+PED | 6 | 120 | Withheld Tac | Itraconazole 250mg qd 4 days | Worsened |
| P12 | Tac/CsA+MMF+Methylprednisolone(MP) | 10 | 99 | Withheld Tac and MP, change to CsA, continued MMF | Liposomal amphotericin B 0.4mg/kg/day 14 days, followed by Itraconazole 200mg bid | Improved |
| P13 | Tac 3.5mg twice daily+MMF 360mg bid+ PED 10 mg qd | 24 | 180 | N | Liposomal amphotericin B 3mg/kg/day 1 week, followed by Itraconazole 200mg bid 6 months | Improved |
| P14 | Fludarabine | 48 | 57 | N | Amphotericin B 1mg/kg/day 10 days | Died |
| P15 | Tac4mg bid+MMF 750 mg bid+ PED7.5mg qd | 28 | N | Reduced Tac dosage, Withheld MMF | Voriconazole 200mg bid 12 months | Improved |
| P16 | Tac+MMF+ MP | 4 | 21 | N | Liposomal amphotericin B 5mg/kg/day 6 months | Improved |
| P17 | Tac+MMF+ PED | 36 | 21 | N | Amphotericin B 5mg qd | Died |
| P18 | Tac+MMF | 12 | N | Reduced dosage and Withheld | Voriconazole 47 days change to Amphotericin B 2 weeks, followed by voriconazole 3 months | Improved |
| P19 | * | 36 | 10 | N | Voriconazole 0.2g bid 2 months | Improved |
| P20 | Tac+MMF | 140 | N | Reduced Tac dosage, Withheld MMF | Amphotericin B 2 weeks, followed by Itraconazole 12 months | Improved |
| P21 | * | 0.5 | N | Used MP | # | Died |
| P22 | Tac+MMF+ PED | 12 | 16 | N | Voriconazole 0.2g qd | Improved |
| P23 | MP+Tac+MMF | 3 | 30 | Reduced dosage | Voriconazole 11 days | Died |
Notes: * indicates that immunosuppressants were used in both P19 and P21, but the types are unknown. bid: twice daily, qd: once daily. N means unknown. # means without antifungal therapy.